Format

Send to

Choose Destination
J Am Coll Cardiol. 2017 Dec 5;70(22):2766-2774. doi: 10.1016/j.jacc.2017.09.1105.

Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial.

Author information

1
David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. Electronic address: jtobis@mednet.ucla.edu.
2
David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
3
Jefferson Headache Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
4
Intermountain Medical Center, Salt Lake City, Utah.
5
Tenet Healthcare Corporation, Boca Raton, Florida.
6
University of Iowa Carver College of Medicine, Iowa City, Iowa.
7
University of Kentucky College of Medicine, Lexington, Kentucky.

Abstract

BACKGROUND:

Migraine is a prevalent and disabling disorder. Patent foramen ovale (PFO) has been associated with migraine, but its role in the disorder remains poorly understood.

OBJECTIVES:

This study examined the efficacy of percutaneous PFO closure as a therapy for migraine with or without aura.

METHODS:

The PREMIUM (Prospective, Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects With Migraine and PFO Using the AMPLATZER PFO Occluder to Medical Management) was a double-blind study investigating migraine characteristics over 1 year in subjects randomized to medical therapy with a sham procedure (right heart catheterization) versus medical therapy and PFO closure with the Amplatzer PFO Occluder device (St. Jude Medical, St. Paul, Minnesota). Subjects had 6 to 14 days of migraine per month, had failed at least 3 migraine preventive medications, and had significant right-to-left shunt defined by transcranial Doppler. Primary endpoints were responder rate defined as 50% reduction in migraine attacks and adverse events. Secondary endpoints included reduction in migraine days and efficacy in patients with versus without aura.

RESULTS:

Of 1,653 subjects consented, 230 were enrolled. There was no difference in responder rate in the PFO closure (45 of 117) versus control (33 of 103) groups. One serious adverse event (transient atrial fibrillation) occurred in 205 subjects who underwent PFO closure. Subjects in the PFO closure group had a significantly greater reduction in headache days (-3.4 vs. -2.0 days/month, p = 0.025). Complete migraine remission for 1 year occurred in 10 patients (8.5%) in the treatment group versus 1 (1%) in the control group (p = 0.01).

CONCLUSIONS:

PFO closure did not meet the primary endpoint of reduction in responder rate in patients with frequent migraine. (Prospective, Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects With Migraine and PFO Using the AMPLATZER PFO Occluder to Medical Management [PREMIUM]; NCT00355056).

KEYWORDS:

Amplatzer PFO Occluder device; aura; double-blind randomized clinical trial; migraine; patent foramen ovale

PMID:
29191325
DOI:
10.1016/j.jacc.2017.09.1105
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center